Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.01−0.09 (-8.18%)
Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%
Tvardi Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Tvardi Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.03M. For fiscal 2025 it was -$23.50M. The highest annual figure on record is $2.83M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.50M | – |
| FY2024 | Dec 31, 2024 | -$18.31M | – |
| FY2023 | Dec 31, 2023 | -$92.08M | – |
| FY2022 | Dec 31, 2022 | -$78.73M | – |
| FY2021 | Dec 31, 2021 | -$60.09M | – |
| FY2020 | Dec 31, 2020 | -$5.49M | – |
| FY2019 | Dec 31, 2019 | -$109.23M | – |
| FY2018 | Dec 31, 2018 | -$22.30M | – |
| FY2017 | Dec 31, 2017 | -$54.83M | – |
| FY2016 | Dec 31, 2016 | -$47.38M | – |
| FY2015 | Dec 31, 2015 | -$21.48M | – |
| FY2014 | Dec 31, 2014 | -$17.64M | -723.6% |
| FY2013 | Dec 31, 2013 | $2.83M | – |
| FY2012 | Dec 31, 2012 | -$6.03M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.23M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.87M | -124.8% |
| Q1 FY2025 | Mar 31, 2025 | -$7.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.66M | – |
| Q2 FY2024 | Jun 30, 2024 | $23.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.25M | -101.5% |
| Q3 FY2021 | Sep 30, 2021 | -$14.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.72M | – |
| Q4 FY2020 | Dec 31, 2020 | $82.09M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.65M | – |
| Q1 FY2020 | Mar 31, 2020 | -$38.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.90M | -160.7% |
| Q1 FY2019 | Mar 31, 2019 | -$27.53M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.49M | – |
| Q2 FY2018 | Jun 30, 2018 | $41.02M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.47M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.41M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.85M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.64M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.19M | – |
| Q3 FY2016 | Sep 30, 2016 | -$12.90M | – |
See a number that looks wrong?